| Entry |
|
|---|
| Name |
Efavirenz (JAN/USP/INN);
Sustiva (TN) |
|---|
| Abbr |
EFV |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C14H9ClF3NO2
|
|---|
| Exact mass |
315.0274
|
|---|
| Mol weight |
315.67
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antiviral
DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI)
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inducer
DG02891 CYP2B6 inducer
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
|
|---|
| Remark |
| Product (mixture): | D10851<US> D11392<US> |
|
|---|
| Efficacy |
Antiviral, Reverse transcriptase inhibitor |
|---|
| Disease |
|
|---|
| Target |
HIV-1 reverse transcriptase [KO: K24802] |
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2B6 [HSA: 1555]
|
|---|
| Interaction |
CYP induction: CYP2B6 [HSA: 1555], CYP3A4 [HSA: 1576]
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AG Non-nucleoside reverse transcriptase inhibitors
J05AG03 Efavirenz
D00896 Efavirenz (JAN/USP/INN) <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Efavirenz
D00896 Efavirenz (JAN/USP/INN)
Drug groups [BR:br08330]
Antiviral
DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI)
D00896 Efavirenz
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
D00896 Efavirenz
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
D00896 Efavirenz
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00896 Efavirenz
Metabolizing enzyme inducer
DG02891 CYP2B6 inducer
D00896 Efavirenz
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
D00896 Efavirenz
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D00896 Efavirenz
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
D00896 Efavirenz (JAN/USP/INN) <US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
D00896 Efavirenz (JAN/USP/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00896
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00896
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00896
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 21
1 C1z C 22.0907 -17.8033
2 C8y C 20.8724 -18.4968
3 C3b C 23.0815 -16.8124
4 O7x O 23.3087 -18.5085
5 C1d C 20.8724 -17.1096
6 C8y C 20.8724 -19.8957
7 C8x C 19.6776 -17.7974
8 C3b C 24.0607 -15.8216
9 C7x C 23.2970 -19.9074
10 X F 19.4676 -17.1039
11 X F 20.4935 -15.7516
12 X F 21.8457 -16.1130
13 N1x N 22.0790 -20.6069
14 C8x C 19.6776 -20.6009
15 C8y C 18.4534 -18.4968
16 C1y C 25.0457 -14.8248
17 O6a O 24.5036 -20.6126
18 C8x C 18.4534 -19.8957
19 X Cl 17.2352 -17.7974
20 C1x C 26.3922 -14.4634
21 C1x C 25.3954 -13.4783
BOND 23
1 1 2 1
2 1 3 1 #Down
3 1 4 1
4 1 5 1 #Up
5 2 6 2
6 2 7 1
7 3 8 3
8 4 9 1
9 5 10 1
10 5 11 1
11 5 12 1
12 6 13 1
13 6 14 1
14 7 15 2
15 8 16 1
16 9 17 2
17 14 18 2
18 15 19 1
19 16 20 1
20 16 21 1
21 9 13 1
22 15 18 1
23 20 21 1
|
|---|
